Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.

Recent News

wugen-logo-400
05/20/2024

Wugen Announces RMAT and PRIME Designations for WU-CART-007 to Accelerate Regulatory Reviews and Plans to Present Positive Phase 2 Study Findings at European Hematology Association (EHA) 2024 in June

READ MORE
Logo-Geneoscopy-400
05/14/2024

Geneoscopy Expands Leadership Team to Support ColoSense™ Rollout and Advance Precision IBD Solution

READ MORE
C4-logo-wht
05/08/2024

C4 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

READ MORE
Logo-Geneoscopy-400
05/06/2024

FDA Approves ColoSense™ - Geneoscopy's Noninvasive Multi-target Stool RNA (mt-sRNA) Colorectal Cancer Screening Test

READ MORE
C4-logo-wht
04/29/2024

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

READ MORE
C4-logo-wht
04/09/2024

C4 Therapeutics to Participate in the Stifel 2024 Targeted Oncology Forum

READ MORE
C4-logo-wht
04/08/2024

C4 Therapeutics Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024

READ MORE
Logo-Geneoscopy-400
04/03/2024

Geneoscopy to Present Research on Inflammatory Bowel Disease at Crohn’s & Colitis Foundation’s IBD Innovate 2024 Conference

READ MORE
wugen-logo-400
03/14/2024

Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies

READ MORE

PORTFOLIO HIGHLIGHTS

WUGEN Logo
White C4 Therapeutics logo
Geneoscopy logo
NextRNA Logo
CareVet Logo
microbial-logo-header300